Contact
searchSearch
HMP Global
Login

Major Depressive Disorder News

a man with depression looks out a window major depressive disorder
News
Psilocybin Produces Mixed Outcomes in Phase 2b MDD Study
04/01/2026
Brionna Mendoza
A Phase 2b randomized clinical trial published in JAMA Psychiatry found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive...
A Phase 2b randomized clinical trial published in JAMA Psychiatry found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive...
A Phase 2b randomized clinical...
04/01/2026
Psych Congress Network
a white jigsaw puzzle of a brain against an orange background with one puzzle piece missing
News
AMPA Receptor Modulation Shows Promise in Major Depressive Disorder Treatment
03/24/2026
Brionna Mendoza
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP...
03/24/2026
Psych Congress Network
a person holds a glass of water and pills
News
Antidepressant Use Patterns May Help Personalize MDD Treatment
03/16/2026
Brionna Mendoza
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in...
03/16/2026
Psych Congress Network
orange pill bottle antidepressant depression major depressive disorder MDD
News
Decision Tool Reduces Antidepressant Dropout in Major Depressive Disorder
03/06/2026
Brionna Mendoza
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
A clinical decision-support...
03/06/2026
Psych Congress Network
psilocybin-containing mushrooms in a beaker
News
Synthetic Psilocybin Meets Primary Endpoint in Phase 3 Treatment-Resistant Depression Trial
02/19/2026
Maria Mantas
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin...
02/19/2026
Psych Congress Network
A man looks out a window
News
Adjunctive Vagus Nerve Stimulation Shows Durable Benefit in Treatment-Resistant Depression
01/20/2026
Maria Mantas
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study...
01/20/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network
brain illustration
News
Blood-Brain Biomarker Signatures Differentiate Early Depression and Psychosis
12/18/2025
Maria Mantas
An analysis from the multicenter PRONIA consortium reports that integrated peripheral inflammatory markers and whole-brain gray matter volumes can distinguish early-stage depression from psychosis.
An analysis from the multicenter PRONIA consortium reports that integrated peripheral inflammatory markers and whole-brain gray matter volumes can distinguish early-stage depression from psychosis.
An analysis from the multicenter...
12/18/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves First At-Home tDCS Treatment for Major Depressive Disorder
12/16/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug...
12/16/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use